- Home
- GWRS vs PSTX Comparison
GWRS vs PSTX Comparison
Compare GWRS & PSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- PSTX
- Stock Information
- Founded
- GWRS 2003
- PSTX 2014
- Country
- GWRS United States
- PSTX United States
- Employees
- GWRS N/A
- PSTX N/A
- Industry
- GWRS Water Supply
- PSTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GWRS Utilities
- PSTX Health Care
- Exchange
- GWRS Nasdaq
- PSTX Nasdaq
- Market Cap
- GWRS 288.9M
- PSTX 249.1M
- IPO Year
- GWRS 2010
- PSTX 2020
- Fundamental
- Price
- GWRS $12.89
- PSTX $2.50
- Analyst Decision
- GWRS
- PSTX Strong Buy
- Analyst Count
- GWRS 0
- PSTX 2
- Target Price
- GWRS N/A
- PSTX $15.00
- AVG Volume (30 Days)
- GWRS 18.8K
- PSTX 533.7K
- Earning Date
- GWRS 11-06-2024
- PSTX 11-07-2024
- Dividend Yield
- GWRS 2.33%
- PSTX N/A
- EPS Growth
- GWRS N/A
- PSTX N/A
- EPS
- GWRS 0.26
- PSTX N/A
- Revenue
- GWRS $52,020,000.00
- PSTX $88,462,000.00
- Revenue This Year
- GWRS $2.72
- PSTX $36.53
- Revenue Next Year
- GWRS $3.56
- PSTX N/A
- P/E Ratio
- GWRS $50.29
- PSTX N/A
- Revenue Growth
- GWRS 5.90
- PSTX N/A
- 52 Week Low
- GWRS $9.34
- PSTX $1.83
- 52 Week High
- GWRS $13.42
- PSTX $4.27
- Technical
- Relative Strength Index (RSI)
- GWRS 56.28
- PSTX 38.80
- Support Level
- GWRS $12.75
- PSTX $2.41
- Resistance Level
- GWRS $13.30
- PSTX $2.61
- Average True Range (ATR)
- GWRS 0.28
- PSTX 0.12
- MACD
- GWRS 0.09
- PSTX -0.01
- Stochastic Oscillator
- GWRS 68.46
- PSTX 24.66
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operate within the State of Arizona.
About PSTX Poseida Therapeutics Inc.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.